BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 34955003)

  • 1. Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound.
    Park J; Lee JM; Kim TH; Yoon JH
    Clin Mol Hepatol; 2022 Jul; 28(3):362-379. PubMed ID: 34955003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Role of Hepatobiliary Magnetic Resonance Contrast Media and Contrast-Enhanced Ultrasound for Noninvasive Diagnosis of Hepatocellular Carcinoma: Emphasis on Recent Updates in Major Guidelines.
    Kim TH; Yoon JH; Lee JM
    Korean J Radiol; 2019 Jun; 20(6):863-879. PubMed ID: 31132813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Contrast-Enhanced Ultrasound and Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI for the Diagnosis of Macroscopic Type of Hepatocellular Carcinoma.
    Iwamoto T; Imai Y; Kogita S; Igura T; Sawai Y; Fukuda K; Yamaguchi Y; Matsumoto Y; Nakahara M; Morimoto O; Seki Y; Ohashi H; Fujita N; Kudo M; Takehara T
    Dig Dis; 2016; 34(6):679-686. PubMed ID: 27750237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma.
    Kobayashi T; Aikata H; Hatooka M; Morio K; Morio R; Kan H; Fujino H; Fukuhara T; Masaki K; Ohno A; Naeshiro N; Nakahara T; Honda Y; Murakami E; Kawaoka T; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Hyogo H; Takahashi S; Chayama K
    Eur Radiol; 2015 Nov; 25(11):3272-81. PubMed ID: 26037713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Contrast-Enhanced Ultrasound as a Second-Line Diagnostic Modality in Noninvasive Diagnostic Algorithms for Hepatocellular Carcinoma.
    Kang HJ; Lee JM; Yoon JH; Han JK
    Korean J Radiol; 2021 Mar; 22(3):354-365. PubMed ID: 33236540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
    Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
    Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm.
    Mita K; Kim SR; Kudo M; Imoto S; Nakajima T; Ando K; Fukuda K; Matsuoka T; Maekawa Y; Hayashi Y
    World J Gastroenterol; 2010 Sep; 16(33):4187-92. PubMed ID: 20806437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
    Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
    Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
    [No Abstract]   [Full Text] [Related]  

  • 10. Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?
    Joo I; Lee JM; Lee DH; Jeon JH; Han JK
    Eur Radiol; 2019 Apr; 29(4):1724-1732. PubMed ID: 30255250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraindividual Comparison of MRIs with Extracellular and Hepatobiliary Contrast Agents for the Noninvasive Diagnosis of Hepatocellular Carcinoma Using the Korean Liver Cancer Association-National Cancer Center 2022 Criteria.
    Yoon JK; Han DH; Lee S; Choi JY; Choi GH; Kim DY; Kim MJ
    Cancer Res Treat; 2023 Jul; 55(3):939-947. PubMed ID: 36791769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance of magnetic resonance imaging and contrast-enhanced ultrasound in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma: a meta-analysis.
    Wu Y; Xia C; Chen J; Qin Q; Ye Z; Song B
    Abdom Radiol (NY); 2024 Jan; 49(1):34-48. PubMed ID: 37823913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of hepatobiliary phase delay time of Gd-EOB-DTPA-enhanced magnetic resonance imaging for identification of hepatocellular carcinoma in patients with cirrhosis of different degrees of severity.
    Wu JW; Yu YC; Qu XL; Zhang Y; Gao H
    World J Gastroenterol; 2018 Jan; 24(3):415-423. PubMed ID: 29391764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnostic performance of contrast-enhanced ultrasound (CEUS) for evaluating hepatocellular carcinoma (HCC) juxtaposed to MRI findings; a retrospective single-center analysis of 292 patients.
    Schwarze V; Marschner C; Völckers W; de Figueiredo GN; Rübenthaler J; Clevert DA
    Clin Hemorheol Microcirc; 2020; 76(2):155-160. PubMed ID: 32925017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening.
    Vietti Violi N; Lewis S; Liao J; Hulkower M; Hernandez-Meza G; Smith K; Babb JS; Chin X; Song J; Said D; Kihira S; Sirlin CB; Reeder SB; Bashir MR; Fowler KJ; Ferket BS; Sigel K; Taouli B
    Eur Radiol; 2020 Nov; 30(11):6003-6013. PubMed ID: 32588209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced ultrasound in detecting hepatocellular carcinoma: A meta-analysis.
    Wang J; Ye X; Li J; He S
    Medicine (Baltimore); 2021 Feb; 100(6):e24602. PubMed ID: 33578564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life assessment of standardized contrast-enhanced ultrasound (CEUS) and CEUS algorithms (CEUS LI-RADS®/ESCULAP) in hepatic nodules in cirrhotic patients-a prospective multicenter study.
    Strobel D; Jung EM; Ziesch M; Praktiknjo M; Link A; Dietrich CF; Klinger C; Schultheiß M; Jesper D; Schellhaas B
    Eur Radiol; 2021 Oct; 31(10):7614-7625. PubMed ID: 33855588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Gadobenate-Enhanced MRI and Gadoxetate-Enhanced MRI for Hepatocellular Carcinoma Detection Using LI-RADS Version 2018: A Prospective Intraindividual Randomized Study.
    Rong D; He B; Tang W; Xie S; Kuang S; Grazioli L; Hussain SM; Yang Y; Wang J
    AJR Am J Roentgenol; 2022 Apr; 218(4):687-698. PubMed ID: 34817191
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of Contrast-Enhanced Ultrasound versus Contrast-Enhanced Magnetic Resonance Imaging for the Diagnosis of Focal Liver Lesions Using the Liver Imaging Reporting and Data System.
    Wang JY; Feng SY; Yi AJ; Zhu D; Xu JW; Li J; Cui XW; Dietrich CF
    Ultrasound Med Biol; 2020 May; 46(5):1216-1223. PubMed ID: 32115307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.
    Paisant A; Vilgrain V; Riou J; Oberti F; Sutter O; Laurent V; Rodes A; Guiu B; Cassinotto C; Trillaud H; Bricault I; Michalak S; Bruno O; Ronot M; Aubé C
    J Hepatol; 2020 May; 72(5):937-945. PubMed ID: 31870951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.